Analyst Reco. Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Real-time Estimate Cboe BZX Other stock markets 15:20:01 02/05/2024 BST			5-day change	1st Jan Change
12.48 ^USD	-0.20%		+7.32%	+52.34%

03-29	General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	CI
03-14	Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	03-14	MT
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating	03-01	MT
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating	02-29	MT
Goldman Sachs Raises Price Target on Iovance Biotherapeutics to $19 From $13, Maintains Buy Rating	02-20	MT
Piper Sandler Adjusts Price Target on Iovance Biotherapeutics to $18 From $14, Maintains Overweight Rating	02-20	MT
Dwindling Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	02-20	MT
Chardan Boosts Price Target on Iovance Biotherapeutics to $34 From $29, Keeps Buy Rating	02-20	MT
HC Wainwright Cuts Price Target on Iovance Biotherapeutics to $28 From $38, Maintains Buy Rating	11-08	MT
Barclays Cuts Price Target on Iovance Biotherapeutics to $18 From $40, Maintains Overweight Rating	18/09/23	MT
Stifel Nicolaus Adjusts Iovance Biotherapeutics Price Target to $25 From $27, Maintains Buy Rating	13/09/23	MT
Wells Fargo Upgrades Iovance Biotherapeutics to Overweight From Equalweight, Raises Price Target to $17 From $11	30/05/23	MT
Stifel Adjusts Price Target on Iovance Biotherapeutics to $24 From $21, Maintains Buy Rating	30/05/23	MT
Baird Adjusts Iovance Biotherapeutics Price Target to $23 From $20, Maintains Outperform Rating	23/05/23	MT
Baird Adjusts Price Target on Iovance Biotherapeutics to $20 From $25, Maintains Outperform Rating	10/05/23	MT
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $11 From $14, Maintains Equal-Weight Rating	06/03/23	MT
Oppenheimer Adjusts Iovance Biotherapeutics' Price Target to $15 From $25, Maintains Outperform Rating	01/03/23	MT
Piper Sandler Upgrades Iovance Biotherapeutics to Overweight From Neutral, Adjusts Price Target to $14 From $11	27/01/23	MT
Truist Securities Adjusts Iovance Biotherapeutics' Price Target to $17 From $16, Keeps Buy Rating	24/01/23	MT
Goldman Sachs Downgrades Iovance Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20	09/12/22	MT
JMP Securities Lowers Price Target on Iovance Biotherapeutics to $21 From $25, Maintains Market Outperform Rating	21/11/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Analyst Reco.

Filters